Teva’s generic Vagifem launches
JERUSALEM — Teva on Monday announced the launch of its generic Vagifem (estradiol vaginal inserts). The drug is indicated to treat atrophic vaginitis due to menopause.
“Our expanding portfolio of oral contraceptives and hormone replacement therapies gives women a broader choice of products to manage their health needs cost-effectively,” Teva CEO and president global generic medicines North America Andy Boyer said. “With this addition, patients and healthcare providers who prefer this unique dosage-form now have another, more affordable option for treatment.”
The drug had U.S. sales of approximately $379 million for the 12 months ended May 2017, according to QuintilesIMS data.